以肠道菌群为靶点的海藻多糖干预代谢综合征的研究进展

Research Progress on Seaweed Polysaccharides Targeting Gut Microbiota to Intervene in Metabolic Syndrome

海藻多糖作为一类具有生物活性的膳食纤维,被用作益生元来改善慢性代谢性疾病,而肠道菌群是海藻多糖发挥功效的潜在靶点。肠道菌群在调控宿主的健康、营养、代谢和免疫稳态等方面起着关键作用。多种海藻多糖不能被人体内消化酶降解,但可以被肠道菌群降解和发酵,产生短链脂肪酸(SCFAs),作为肠道微生物的能量来源,并通过调节菌群结构与宿主肠道稳态,影响肠道微生态环境。此外,SCFAs和肠道菌群的改变与代谢疾病的发生发展密切相关。本文综述了海藻多糖与肠道菌群的相互作用以及对代谢综合征的影响的研究进展。

Seaweed polysaccharides, a class of biologically active dietary fiber, are used as prebiotics to improve chronic metabolic diseases.Gut microbiota is a potential target for the efficacy of seaweed polysaccharides, which plays a key role in the regulation of host health, nutrition, metabolism and immune homeostasis.A variety of seaweed polysaccharides cannot be degraded by digestive enzymes in the body, but can be degraded and fermented by gut microbiota to produce short-chain fatty acids(SCFAs),which serve as a source of energy for intestinal microorganisms and influence the intestinal microecological environment by regulating the microbiota and host gut homeostasis.Furthermore, alterations in SCFAs and gut microbiota are closely associated with the development of metabolic diseases. Therefore, this paper reviewed the research progress on interaction between seaweed polysaccharides and gut microbiota and their effects on metabolic syndrome.